Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H30N6O4S |
Molecular Weight | 474.5783 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCc1c2c(c(=O)[nH]c(-c3cc(ccc3OCC)S(=O)(=O)N4CCN(C)CC4)n2)n(C)n1
InChI
InChIKey=BNRNXUUZRGQAQC-UHFFFAOYSA-N
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
Molecular Formula | C22H30N6O4S |
Molecular Weight | 474.5783 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sildenafil (Viagra, Revatio) is a PDE5 inhibitor which was approved by FDA for the treatment of erectile disfunction and adults with pulmonary arterial hypertension. Upon administration sildenafil inhibits PDE5 and results in elevated level of cyclic guanosine monophosphate and smooth muscle relaxation.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18388248
Curator's Comment:: CNS activity was observed on rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1827 |
3.5 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | VIAGRA Approved UseVIAGRA is a phosphodiesterase-5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction. Launch Date8.9095681E11 |
|||
Primary | REVATIO Approved UseREVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Launch Date1.11775685E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
159 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11879254 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SILDENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
530 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11879254 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SILDENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.07 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/11879254 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
SILDENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SILDENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
SILDENAFIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: Page: p.2 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: M Population Size: 1 Sources: Page: p.2 |
Disc. AE: Flushing, Headache... AEs leading to discontinuation/dose reduction: Flushing Sources: Page: p.2Headache Tachycardia (mild) |
2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: Page: p.2 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: M Population Size: 1 Sources: Page: p.2 |
Disc. AE: Visual field defect... AEs leading to discontinuation/dose reduction: Visual field defect Sources: Page: p.2 |
250 mg single, oral Overdose Dose: 250 mg Route: oral Route: single Dose: 250 mg Sources: Page: p.258 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.258 |
Disc. AE: Rhabdomyolysis, Visual disturbance NOS... AEs leading to discontinuation/dose reduction: Rhabdomyolysis Sources: Page: p.258Visual disturbance NOS |
80 mg 3 times / day multiple, oral Highest studied dose Dose: 80 mg, 3 times / day Route: oral Route: multiple Dose: 80 mg, 3 times / day Sources: Page: p.1278 |
unhealthy, 47.5 n = 135 Health Status: unhealthy Condition: Pulmonary arterial hypertension Age Group: 47.5 Sex: M+F Population Size: 135 Sources: Page: p.1278 |
|
6.5 g single, oral Overdose Dose: 6.5 g Route: oral Route: single Dose: 6.5 g Sources: Page: p.1 |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: Page: p.1 |
Disc. AE: Vomiting, Blurred vision... AEs leading to discontinuation/dose reduction: Vomiting (severe) Sources: Page: p.1Blurred vision Sinus tachycardia |
600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: |
Disc. AE: Cardiomegaly, Fibrosis myocardial... AEs leading to discontinuation/dose reduction: Cardiomegaly (grade 5) Sources: Fibrosis myocardial (grade 5) |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (0.32%) Sources: Page: p.1400Vomiting (0.32%) Leg pain (0.32%) Backache (0.32%) Intermittent headache (0.32%) Dyspepsia (0.32%) Headache (0.32%) |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1403 |
unhealthy, 60 n = 163 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 163 Sources: Page: p.1403 |
Disc. AE: Headache, Flushing... AEs leading to discontinuation/dose reduction: Headache (0.61%) Sources: Page: p.1403Flushing (0.61%) |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1401 |
unhealthy, 60 n = 225 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 225 Sources: Page: p.1401 |
Disc. AE: Headache, Flushing... AEs leading to discontinuation/dose reduction: Headache (0.9%) Sources: Page: p.1401Flushing (0.44%) Blurred vision (0.44%) Groin pain (1.3%) |
400 mg single, oral Overdose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: Page: p.1,2 |
unhealthy, 67 n = 1 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 67 Sex: M Population Size: 1 Sources: Page: p.1,2 |
Disc. AE: Acute kidney injury... AEs leading to discontinuation/dose reduction: Acute kidney injury Sources: Page: p.1,2 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Flushing | Disc. AE | 2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: Page: p.2 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: M Population Size: 1 Sources: Page: p.2 |
Headache | Disc. AE | 2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: Page: p.2 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: M Population Size: 1 Sources: Page: p.2 |
Tachycardia | mild Disc. AE |
2000 mg single, oral Overdose Dose: 2000 mg Route: oral Route: single Dose: 2000 mg Sources: Page: p.2 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: M Population Size: 1 Sources: Page: p.2 |
Visual field defect | Disc. AE | 2400 mg single, oral Overdose Dose: 2400 mg Route: oral Route: single Dose: 2400 mg Sources: Page: p.2 |
healthy, 33 n = 1 Health Status: healthy Age Group: 33 Sex: M Population Size: 1 Sources: Page: p.2 |
Rhabdomyolysis | Disc. AE | 250 mg single, oral Overdose Dose: 250 mg Route: oral Route: single Dose: 250 mg Sources: Page: p.258 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.258 |
Visual disturbance NOS | Disc. AE | 250 mg single, oral Overdose Dose: 250 mg Route: oral Route: single Dose: 250 mg Sources: Page: p.258 |
unhealthy, 45 n = 1 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 45 Sex: M Population Size: 1 Sources: Page: p.258 |
Blurred vision | Disc. AE | 6.5 g single, oral Overdose Dose: 6.5 g Route: oral Route: single Dose: 6.5 g Sources: Page: p.1 |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: Page: p.1 |
Sinus tachycardia | Disc. AE | 6.5 g single, oral Overdose Dose: 6.5 g Route: oral Route: single Dose: 6.5 g Sources: Page: p.1 |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: Page: p.1 |
Vomiting | severe Disc. AE |
6.5 g single, oral Overdose Dose: 6.5 g Route: oral Route: single Dose: 6.5 g Sources: Page: p.1 |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: Page: p.1 |
Cardiomegaly | grade 5 Disc. AE |
600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: |
Fibrosis myocardial | grade 5 Disc. AE |
600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: |
healthy, 56 n = 1 Health Status: healthy Age Group: 56 Sex: M Population Size: 1 Sources: |
Backache | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Dyspepsia | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Headache | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Intermittent headache | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Leg pain | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Nausea | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Vomiting | 0.32% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1400 |
unhealthy, 58 n = 316 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 58 Sex: M Population Size: 316 Sources: Page: p.1400 |
Flushing | 0.61% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1403 |
unhealthy, 60 n = 163 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 163 Sources: Page: p.1403 |
Headache | 0.61% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1403 |
unhealthy, 60 n = 163 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 163 Sources: Page: p.1403 |
Blurred vision | 0.44% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1401 |
unhealthy, 60 n = 225 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 225 Sources: Page: p.1401 |
Flushing | 0.44% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1401 |
unhealthy, 60 n = 225 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 225 Sources: Page: p.1401 |
Headache | 0.9% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1401 |
unhealthy, 60 n = 225 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 225 Sources: Page: p.1401 |
Groin pain | 1.3% Disc. AE |
100 mg 1 times / day multiple, oral (max) Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: Page: p.1401 |
unhealthy, 60 n = 225 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 60 Sex: M Population Size: 225 Sources: Page: p.1401 |
Acute kidney injury | Disc. AE | 400 mg single, oral Overdose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: Page: p.1,2 |
unhealthy, 67 n = 1 Health Status: unhealthy Condition: Erectile dysfunction Age Group: 67 Sex: M Population Size: 1 Sources: Page: p.1,2 |
PubMed
Title | Date | PubMed |
---|---|---|
A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. | 2001 |
|
Use of sildenafil in penile implant patients. | 2001 |
|
'Viagra effect' - influence of mass media on patient behavior. | 2001 |
|
Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy. | 2001 Apr |
|
Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. | 2001 Apr |
|
Intracavernosal injection of sildenafil citrate: misapplication of the drug. | 2001 Apr |
|
Oral alpha adrenoceptor blockade as a treatment of erectile dysfunction. | 2001 Feb |
|
Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. | 2001 Feb |
|
I've heard of an herbal alternative to Viagra for impotence. Does it work and is it safe? | 2001 Feb |
|
Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. | 2001 Feb |
|
Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. | 2001 Feb |
|
Interposition sural nerve grafting during radical retropubic prostatectomy. | 2001 Feb |
|
Sildenafil modulates hemodynamics and pulmonary gas exchange. | 2001 Feb |
|
Viagra for impotence of pulmonary vasodilator therapy? | 2001 Feb |
|
Should male patients with chest pain be questioned about Viagra use during triage screening? | 2001 Feb |
|
Sex and the heart: what is the role of the cardiologist? | 2001 Feb |
|
Are things looking up for the treatment of gastroparesis? Sildenafil in animal models of diabetic gastropathy. | 2001 Feb |
|
Sildenafil-mediated reduction in retinal function in heterozygous mice lacking the gamma-subunit of phosphodiesterase. | 2001 Feb |
|
[Endocrinology 1999-2000]. | 2001 Feb 15 |
|
Cost-effectiveness of sildenafil. | 2001 Feb 6 |
|
Cost-effectiveness of sildenafil. | 2001 Feb 6 |
|
Cost-effectiveness of sildenafil. | 2001 Feb 6 |
|
The role of nitric oxide in penile erection. | 2001 Jan |
|
Sildenafil citrate: a therapeutic update. | 2001 Jan |
|
Intracavernosal injection therapy. Does it still have a role in erectile dysfunction? | 2001 Jan |
|
Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. | 2001 Jan |
|
Sexual aspects of headache. How sexual function relates to headaches and their causes and treatment. | 2001 Jan |
|
pH-mediated field-amplified sample stacking of pharmaceutical cations in high-ionic strength samples. | 2001 Jan |
|
Viagra: are anaesthetists rising to the challenge? | 2001 Jan |
|
Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians. | 2001 Jan |
|
Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. | 2001 Jan |
|
[Prescribing of sildenafil by national insurance program physicians. What basic sexual medicine qualification is required?]. | 2001 Jan 11 |
|
[Erectile dysfunction in coronary heart disease. No fear about the blue pill]. | 2001 Jan 18 |
|
[Paths to sexual satisfaction. What will stimulate the tired man?]. | 2001 Jan 18 |
|
Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries. | 2001 Jan 26 |
|
Regulation of human PDE5A2 intronic promoter by cAMP and cGMP: identification of a critical Sp1-binding site. | 2001 Jan 26 |
|
Identification and regulation of human PDE5A gene promoter. | 2001 Jan 26 |
|
[Drug treatment of erection disorders in patients with cardiovascular disease]. | 2001 Jan 27 |
|
Viagra: a three-year sexual revolution and the need to recognise its role within the NHS. | 2001 Mar |
|
Initial uptake in use of sildenafil in general practice. | 2001 Mar |
|
Anterior ischemic optic neuropathy associated with viagra. | 2001 Mar |
|
Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil. | 2001 Mar |
|
Sildenafil citrate and sperm function. | 2001 Mar |
|
Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. | 2001 Mar |
|
In vivo and in vitro investigation of the effects of sildenafil on rat cavernous smooth muscle. | 2001 Mar |
|
Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats. | 2001 Mar |
|
Clinical efficacy of sildenafil in patients on chronic dialysis. | 2001 Mar |
|
Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. | 2001 Mar 17 |
|
Narrowbore high-performance liquid chromatography for the simultaneous determination of sildenafil and its metabolite UK-103,320 in human plasma using column switching. | 2001 Mar 5 |
|
Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. | 2001 May |
Sample Use Guides
Erectile disfunction: For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. Pulmonary arterial hypertension: 5 mg or 20 mg three times a day, 46 hours apart (oral); 2.5 mg or 10 mg three times a day administered as an intravenous bolus injection.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 15:33:35 UTC 2021
by
admin
on
Sat Jun 26 15:33:35 UTC 2021
|
Record UNII |
3M7OB98Y7H
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2127
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
VIZARSIN (AUTHORIZED: ERECTILE DYSFUNCTION)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
REVATIO (AUTHORIZED: HYPERTENSION, PULMONARY)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
WHO-VATC |
QG04BE03
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
VIAGRA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
NDF-RT |
N0000175599
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
NDF-RT |
N0000020026
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
SILDENAFIL RATIOPHARM (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
PATREX (WITHDRAWN: ERECTILE DYSFUNCTIONS)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
SILDENAFIL ACTAVIS (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
FDA ORPHAN DRUG |
344211
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EMA ASSESSMENT REPORTS |
SILDENAFIL TEVA (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
WHO-ATC |
G04BE03
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
EU-Orphan Drug |
EU/3/17/1885
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
||
|
LIVERTOX |
885
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SILDENAFIL
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
SUB10517MIG
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
C61940
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
2441
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
3M7OB98Y7H
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
139755-83-2
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
136411
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | RxNorm | ||
|
CHEMBL192
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
135398744
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
7374
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
7305
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
4743
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
C101426
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
139755-83-2
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
M9898
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | Merck Index | ||
|
Sildenafil
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY | |||
|
DB00203
Created by
admin on Sat Jun 26 15:33:36 UTC 2021 , Edited by admin on Sat Jun 26 15:33:36 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR |
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |